{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:54:12Z","timestamp":1740142452851,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s42770-021-00433-2","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T23:02:50Z","timestamp":1611356570000},"page":"597-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of the in vitro activity of azithromycin niosomes alone and in combination with levofloxacin on extensively drug-resistant Klebsiella pneumoniae clinical isolates"],"prefix":"10.1007","volume":"52","author":[{"given":"Hoda Mohamed","family":"Owais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal Mohammad","family":"Baddour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala Abd El-Raouf","family":"El-Metwally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba Soliman","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour Sherif","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7122-4760","authenticated-orcid":false,"given":"Marwa Ahmed","family":"Meheissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"issue":"1","key":"433_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-019-0343-8","volume":"19","author":"CY Effah","year":"2020","unstructured":"Effah CY, Sun T, Liu S, Wu Y (2020) Klebsiella pneumoniae: an increasing threat to public health. Ann Clin Microbiol Antimicrob 19(1):1. https:\/\/doi.org\/10.1186\/s12941-019-0343-8","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"433_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fchem.2020.00286","volume":"8","author":"YC Yeh","year":"2020","unstructured":"Yeh YC, Huang TH, Yang SC, Chen CC, Fang JY (2020) Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front Chem 8:286. https:\/\/doi.org\/10.3389\/fchem.2020.00286","journal-title":"Front Chem"},{"issue":"1","key":"433_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos E, Rodriguez-Torres M, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16(1):71. https:\/\/doi.org\/10.1186\/s12951-018-0392-8","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"433_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/pharmaceutics11020055","volume":"11","author":"X Ge","year":"2019","unstructured":"Ge X, Wei M, He S, Yuan WE (2019) Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics 11(2):55. https:\/\/doi.org\/10.3390\/pharmaceutics11020055","journal-title":"Pharmaceutics"},{"key":"433_CR5","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. http:\/\/www.eucast.org.\""},{"key":"433_CR6","unstructured":"Tille P (2017) Bailey and Scott\u2019s diagnostic microbiology. 14th. St Louis, Missouri, Mosby Elsevier"},{"issue":"3","key":"433_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"433_CR8","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1208\/s12249-014-0141-8","volume":"15","author":"HS Barakat","year":"2014","unstructured":"Barakat HS, Kassem MA, El-Khordagui LK, Khalafallah NM (2014) Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces. AAPS PharmSciTech 15(5):1263\u20131274. https:\/\/doi.org\/10.1208\/s12249-014-0141-8","journal-title":"AAPS PharmSciTech"},{"issue":"1\u20132","key":"433_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijpharm.2005.11.045","volume":"311","author":"M Manconi","year":"2006","unstructured":"Manconi M, Sinico C, Valenti D, Lai F, Fadda AM (2006) Niosomes as carriers for tretinoin. III A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm 311(1\u20132):11\u201319. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.11.045","journal-title":"Int J Pharm"},{"key":"433_CR10","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2012) Methods for dilution antimicrobial susceptibility tests f or bacteria that grow aerobically; Approved Standard\u2014Ninth Edition. CLSI document M07-A9. Wayne: Clinical and Laboratory Standards Institute"},{"key":"433_CR11","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2020) Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute"},{"key":"433_CR12","doi-asserted-by":"publisher","DOI":"10.1201\/9781420014495","volume-title":"Antimicrobial susceptibility testing protocols","author":"R Schwalbe","year":"2007","unstructured":"Schwalbe R, Steele-Moore L, Goodwin AC (2007) Antimicrobial susceptibility testing protocols. CRC Press, New York"},{"key":"433_CR13","first-page":"5.12.1","volume-title":"Clinical microbiology procedures handbook, 2nd edition update","author":"J Moody","year":"2007","unstructured":"Moody J (2007) Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Garcia LS, Isenberg HD (eds) Clinical microbiology procedures handbook, 2nd edition update. ASM Press, Washington, DC, pp 5.12.1\u20135.12.23"},{"issue":"4Pt1","key":"433_CR14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1164\/ajrccm.161.4.9907147","volume":"161","author":"SD Aaron","year":"2000","unstructured":"Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE (2000) Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 161(4Pt1):1206\u20131212. https:\/\/doi.org\/10.1164\/ajrccm.161.4.9907147","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"433_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jac\/dkh140","volume":"53","author":"JP Lavigne","year":"2004","unstructured":"Lavigne JP, Bonnet R, Michaux-Charachon S, Jourdan J, Caillon J, Sotto A (2004) Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria. J Antimicrob Chemother 53(4):616\u2013619. https:\/\/doi.org\/10.1093\/jac\/dkh140","journal-title":"J Antimicrob Chemother"},{"issue":"24.08","key":"433_CR16","first-page":"79","volume":"140","author":"Y Chan","year":"2003","unstructured":"Chan Y (2003) Biostatistics 102: quantitative data\u2013parametric & non-parametric tests. Blood Press 140(24.08):79","journal-title":"Blood Press"},{"issue":"1","key":"433_CR17","doi-asserted-by":"publisher","first-page":"1901872","DOI":"10.1002\/advs.201901872","volume":"7","author":"YX Ma","year":"2019","unstructured":"Ma YX, Wang CY, Li YY, Li J, Wan QQ, Chen JH, Tay FR, Niu LN (2019) Considerations and caveats in combating ESKAPE pathogens against nosocomial infections. Adv Sci (Weinh) 7(1):1901872. https:\/\/doi.org\/10.1002\/advs.201901872","journal-title":"Adv Sci (Weinh)"},{"issue":"02","key":"433_CR18","doi-asserted-by":"publisher","first-page":"056","DOI":"10.7324\/JAPS.2020.102009","volume":"10","author":"W Santimaleeworagun","year":"2020","unstructured":"Santimaleeworagun W, Thunyaharn S, Juntanawiwat P, Thongnoy N, Harindhanavudhi S, Nakeesathit S, Teschumroon S (2020) The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia. J Appl Pharm Sci 10(02):056\u2013059. https:\/\/doi.org\/10.7324\/JAPS.2020.102009","journal-title":"J Appl Pharm Sci"},{"issue":"12","key":"433_CR19","doi-asserted-by":"publisher","first-page":"1106.e1","DOI":"10.1016\/j.cmi.2015.08.001","volume":"21","author":"DR Giacobbe","year":"2015","unstructured":"Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M, Mantengoli E, Saffioti C, Pagani N, Tedeschi S, Spanu T, Rossolini GM, Marchese A, Ambretti S, Cauda R, Viale P, Viscoli C, Tumbarello M, ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva) (2015) Risk factors for bloodstream infections due to colistin-resistant KPC-producing klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 21(12):1106.e1\u20131106.e8. https:\/\/doi.org\/10.1016\/j.cmi.2015.08.001","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"433_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/03639045.2017.1291667","volume":"43","author":"S Ullah","year":"2017","unstructured":"Ullah S, Shah MR, Shoaib M, Imran M, Shah SW, Ali I, Ahmed F (2017) Creatinine-based non-phospholipid vesicular carrier for improved oral bioavailability of azithromycin. Drug Dev Ind Pharm 43(6):1011\u20131022. https:\/\/doi.org\/10.1080\/03639045.2017.1291667","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"433_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/1040841X.2015.1136261","volume":"43","author":"C Gomes","year":"2017","unstructured":"Gomes C, Mart\u00ednez-Puchol S, Palma N, Horna G, Ruiz-Rold\u00e1n L, Pons MJ, Ruiz J (2017) Macrolide resistance mechanisms in Enterobacteriaceae: focus on azithromycin. Crit Rev Microbiol 43(1):1\u201330. https:\/\/doi.org\/10.3109\/1040841X.2015.1136261","journal-title":"Crit Rev Microbiol"},{"issue":"2","key":"433_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/pharmaceutics12020142","volume":"12","author":"NE Eleraky","year":"2020","unstructured":"Eleraky NE, Allam A, Hassan SB, Omar MM (2020) Nanomedicine fight against antibacterial resistance: an overview of the recent pharmaceutical innovations. Pharmaceutics 12(2):142. https:\/\/doi.org\/10.3390\/pharmaceutics12020142","journal-title":"Pharmaceutics"},{"issue":"3","key":"433_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/jobm.201900454","volume":"60","author":"S Khan","year":"2020","unstructured":"Khan S, Akhtar MU, Khan S, Javed F, Khan AA (2020) Nanoniosome-encapsulated levoflaxicin as an antibacterial agent against Brucella. J Basic Microbiol 60(3):281\u2013290. https:\/\/doi.org\/10.1002\/jobm.201900454","journal-title":"J Basic Microbiol"},{"key":"433_CR24","doi-asserted-by":"publisher","first-page":"118580","DOI":"10.1016\/j.ijpharm.2019.118580","volume":"569","author":"R Ghafelehbashi","year":"2019","unstructured":"Ghafelehbashi R, Akbarzadeh I, Tavakkoli Yaraki M, Lajevardi A, Fatemizadeh M, Heidarpoor Saremi L (2019) Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm 569:118580. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118580","journal-title":"Int J Pharm"},{"issue":"4","key":"433_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijantimicag.2014.11.008","volume":"45","author":"H Saini","year":"2015","unstructured":"Saini H, Chhibber S, Harjai K (2015) Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections. Int J Antimicrob Agents 45(4):359\u2013367. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.11.008","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"433_CR26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1128\/aac.46.4.1105-1107.2002","volume":"46","author":"L Saiman","year":"2002","unstructured":"Saiman L, Chen Y, Gabriel PS, Knirsch C (2002) Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 46(4):1105\u20131107. https:\/\/doi.org\/10.1128\/aac.46.4.1105-1107.2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"433_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1179\/joc.2011.23.6.350","volume":"23","author":"A Kolumbi\u0107 Lakos","year":"2011","unstructured":"Kolumbi\u0107 Lakos A, Skerk V, Malekovi\u0107 G, Dujni\u0107 Spoljarevi\u0107 T, Kovacic D, Pasini M, Markoti\u0107 A, Magri V, Perletti G (2011) A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study. J Chemother 23(6):350\u2013353. https:\/\/doi.org\/10.1179\/joc.2011.23.6.350","journal-title":"J Chemother"},{"issue":"6","key":"433_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/aja.2011.36","volume":"13","author":"V Magri","year":"2011","unstructured":"Magri V, Montanari E, \u0160kerk V, Markoti\u0107 A, Marras E, Restelli A, Naber KG, Perletti G (2011) Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Androl 13(6):819\u2013827. https:\/\/doi.org\/10.1038\/aja.2011.36","journal-title":"Asian J Androl"},{"issue":"5","key":"433_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/jac\/dkv487","volume":"71","author":"M Kumaraswamy","year":"2016","unstructured":"Kumaraswamy M, Lin L, Olson J, Sun CF, Nonejuie P, Corriden R, D\u00f6hrmann S, Ali SR, Amaro D, Rohde M, Pogliano J, Sakoulas G, Nizet V (2016) Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. J Antimicrob Chemother 71(5):1264\u20131269. https:\/\/doi.org\/10.1093\/jac\/dkv487","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"433_CR30","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.3390\/antibiotics9050218","volume":"9","author":"M Meerwein","year":"2020","unstructured":"Meerwein M, Tarnutzer A, B\u00f6ni M, Van Bambeke F, Hombach M, Zinkernagel AS (2020) Increased azithromycin susceptibility of multidrug-resistant gram-negative bacteria on RPMI-1640 agar assessed by disk diffusion testing. Antibiotics (Basel) 9(5):E218. https:\/\/doi.org\/10.3390\/antibiotics9050218","journal-title":"Antibiotics (Basel)"},{"issue":"12","key":"433_CR31","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00922-10","volume":"54","author":"NC Gordon","year":"2010","unstructured":"Gordon NC, Png K, Wareham DW (2010) Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 54(12):5316\u20135322. https:\/\/doi.org\/10.1128\/AAC.00922-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"433_CR32","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.05996-11","volume":"56","author":"C Vidaillac","year":"2012","unstructured":"Vidaillac C, Benichou L, Duval RE (2012) In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 56(9):4856\u20134861. https:\/\/doi.org\/10.1128\/AAC.05996-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"433_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/IM9.0000000000000014","volume":"2","author":"ER Ulloa","year":"2020","unstructured":"Ulloa ER, Kousha A, Tsunemoto H, Pogliano J, Licitra C, LiPuma J, Sakoulas G, Nizet V, Kumaraswamy M (2020) Azithromycin exerts bactericidal activity and enhances innate immune mediated killing of MDR Achromobacter xylosoxidans. Infect Microb Dis 2(1):10\u201317. https:\/\/doi.org\/10.1097\/IM9.0000000000000014","journal-title":"Infect Microb Dis"},{"issue":"7","key":"433_CR34","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ebiom.2015.05.021","volume":"2","author":"L Lin","year":"2015","unstructured":"Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q, Kumaraswamy M, Rivera H Jr, Corriden R, Rohde M, Hensler ME, Burkart MD, Pogliano J, Sakoulas G, Nizet V (2015) Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens. EBioMedicine 2(7):690\u2013698. https:\/\/doi.org\/10.1016\/j.ebiom.2015.05.021","journal-title":"EBioMedicine"},{"issue":"11","key":"433_CR35","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1128\/AAC.00981-16","volume":"60","author":"DN Bremmer","year":"2016","unstructured":"Bremmer DN, Bauer KA, Pouch SM, Thomas K, Smith D, Goff DA, Pancholi P, Balada-Llasat JM (2016) Correlation of checkerboard synergy testing with time-kill analysis and clinical outcomes of extensively drug-resistant Acinetobacter baumannii respiratory infections. Antimicrob Agents Chemother 60(11):6892\u20136895. https:\/\/doi.org\/10.1128\/AAC.00981-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"433_CR36","doi-asserted-by":"publisher","first-page":"e02549","DOI":"10.1128\/AAC.02549-18","volume":"63","author":"RK Flamm","year":"2019","unstructured":"Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D (2019) Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against gram-negative bacterial strains by using time-kill curves. Antimicrob Agents Chemother 63(5):e02549\u2013e02518. https:\/\/doi.org\/10.1128\/AAC.02549-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"433_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1089\/mdr.2015.0160","volume":"22","author":"ML Mezzatesta","year":"2016","unstructured":"Mezzatesta ML, Caio C, Gona F, Zingali T, Salerno I, Stefani S (2016) Colistin increases the cidal activity of antibiotic combinations against multidrug-resistant Klebsiella pneumoniae: an in vitro model comparing multiple combination bactericidal testing at one peak serum concentration and time-kill method. Microb Drug Resist 22(5):360\u2013363. https:\/\/doi.org\/10.1089\/mdr.2015.0160","journal-title":"Microb Drug Resist"},{"issue":"12","key":"433_CR38","first-page":"615","volume":"16","author":"EA Debbia","year":"1990","unstructured":"Debbia EA, Molinari G, Paglia P, Schito GC (1990) Post-antibiotic effect of azithromycin on respiratory tract pathogens. Drugs Exp Clin Res 16(12):615\u2013619","journal-title":"Drugs Exp Clin Res"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-021-00433-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42770-021-00433-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-021-00433-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T04:37:27Z","timestamp":1620362247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42770-021-00433-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1007\/s42770-021-00433-2","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"type":"print","value":"1517-8382"},{"type":"electronic","value":"1678-4405"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not required","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author accepts the responsibility for releasing this material on behalf of any and all co-authors. This transfer of publication rights covers the nonexclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline, online), or any other reproductions of similar nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}}]}}